Researchers at the University of East Anglia have developed a new drug that works against all of the main types of primary bone cancer. Cancer that starts in the bones, rather than cancer that has spread to the bones, predominantly affects children. Current treatment is gruelling, with outdated chemotherapy cocktails and limb amputation. Despite all of this, the five-year survival rate is poor at just 42 per cent – largely because of how rapidly bone cancer spreads to the lungs. But a new study published today shows how a new drug called ‘CADD522’ blocks a gene associated with driving the
Bone cancer drug could save children’s lives as seen on The Hippocratic Post.